Bruton’s tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy
Open Access
- 28 October 2025
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7907-7909
Abstract
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by immune-mediated platelet destruction and impaired platelet production, leading to bleeding risk, morbidity, and reduced quality of life. Incomplete responses, adverse effects, and relapses are the limitations of current treatments, which include corticosteroids, intravenous immunoglobulin, rituximab, and thrombopoietin receptor agonists. On 29 August 2025, the U.S. Food and Drug Administration (FDA) approved Wayrilz (rilzabrutinib), a first-in-class oral Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with chronic or persistent ITP who have had an insufficient response to previous treatments. Through modulation of both Fc receptor and B-cell receptor signaling, the agent aims to address disease pathophysiology as a treatment that is disease-modifying in nature rather than simplistically dealing with symptoms. Clinical trials, including the key LUNA 3 trial, have shown good efficacy and safety, with durable platelet responses and minimal severe adverse events. This editorial examines rilzabrutinib’s scientific justification, clinical data, comparative analysis, side effects, financial ramifications, and potential applications in the treatment of ITP.Keywords
This publication has 7 references indexed in Scilit:
- A 1-year-old child with essential thrombocythemiaBlood, 2024
- Rilzabrutinib, an Oral BTK Inhibitor, in Immune ThrombocytopeniaNew England Journal of Medicine, 2022
- American Society of Hematology 2019 guidelines for immune thrombocytopeniaBlood Advances, 2019
- Updated international consensus report on the investigation and management of primary immune thrombocytopeniaBlood Advances, 2019
- Properties of mouse and human IgG receptors and their contribution to disease modelsBlood, 2012
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Immune Thrombocytopenic PurpuraNew England Journal of Medicine, 2002